Contents lists available at ScienceDirect



Current Research in Microbial Sciences



journal homepage: www.elsevier.com/locate/crmicr

Evaluation of the susceptibility and fatality of lung cancer patients towards the COVID-19 infection: A systemic approach through analyzing the ACE2, CXCL10 and their co-expressed genes



Tousif Bin Mahmood^a, Afrin Sultana Chowdhury^{a,*}, Mohammad Uzzal Hossain^b, Mehedee Hasan^a, Shagufta Mizan^c, Md. Mezbah-Ul-Islam Aakil^a, Mohammad Imran Hossan^a

^a Department of Biotechnology and Genetic Engineering, Noakhali Science and Technology University, Noakhali 3814, Bangladesh

^b Bioinformatics Division, National Institute of Biotechnology, Dhaka 1349, Bangladesh

^c Department of Genetic Engineering and Biotechnology, University of Chittagong, Chittagong 4331, Bangladesh

ARTICLE INFO

Keywords: COVID-19 SARS-CoV-2 Lung cancer ACE2 CXCL10 Biomarker

ABSTRACT

Coronavirus disease-2019 (COVID-19) is a recent world pandemic disease that is caused by a newly discovered strain of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS- CoV-2). Patients with comorbidities are most vulnerable to this disease. Therefore, cancer patients are reported to be more susceptible to COVID-19 infection, particularly lung cancer patients. To evaluate the probable reasons behind the excessive susceptibility and fatality of lung cancer patients to COVID-19 infection, we targeted the two most crucial agents, Angiotensinconverting enzyme 2 (ACE2) and C-X-C motif 10 (CXCL10). ACE2 is a receptor protein that plays a vital role in the entry of SARS-CoV-2 into the host cell and CXCL10 is a cytokine mainly responsible for the lung cell damage involving in a cytokine storm. By using the UALCAN and GEPIA2 databases, we observed that ACE2 and CXCL10 are mostly overexpressed in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). We then identified the functional significance of ACE2 and CXCL10 in lung cancer development by determining the genetic alteration frequency in their amino acid sequences using the cBioPortal web portal. Lastly, we did the pathological assessment of targeted genes using the PANTHER database. Here, we found that ACE2 and CXCL10 along with their commonly co-expressed genes are involved respectively in the binding activity and immune responses in case of lung cancer and COVID-19 infection. Finally, based on this systemic analysis, we concluded that ACE2 and CXCL10 are two possible biomarkers responsible for the higher susceptibility and fatality of lung cancer patients towards the COVID-19.

1. Introduction

Zoonotic diseases have been a significant concern of public health in the previous decades. Pandemics like Influenza, London plague, smallpox, Spanish flu, AIDS majorly stand examples of cross-species transmission (CST) in several viruses and their fatality rates impose the severity of zoonotic diseases in global populations (Faria et al., 2013, Shereen et al., 2020, Spinelli, 2020). Similar to previous epidemics and pandemics, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19) is in no way behind in the race of body counts, which to date stands at a 102,635,329 infections and 2,216,420 deaths as of the record of Coronavirus Resource Center of John Hopkins University (JHU) (Dong et al., 2020, Jennifer, 2020). Although vaccines against COVID-19 have already been formulated, developed and being administered, COVID-19 still requires attention in terms of its clinical outcomes in patients with comorbidities as well as those who are immunocompromised.

When it comes to analyzing risk groups, initial studies on COVID-19 have pinpointed that people with comorbidities like diabetes, hypertension, carcinoma, cardiovascular disease, chronic kidney disease are more susceptible to SARS-CoV-2 infections as well as being exposed to a more severe prognosis of COVID-19 (Zhou et al., 2020, Yang et al., 2020). However, within this risk cohort, people with cancer are comparatively more vulnerable to COVID-19 rather than people having other underlying clinical complications due to having a more suppressed and compromised immunity as well as not being able to access the required follow-up therapeutic procedures due to the restrictions imposed because of COVID-19 (Saini et al., 2020).

As COVID-19 is a disease of the respiratory tract, previous studies have concluded that patients with lung cancer often experience severe manifestations when infected by SARS-CoV-2 and are at a higher mor-

* Corresponding author.

E-mail address: afrin.bge@nstu.edu.bd (A.S. Chowdhury).

https://doi.org/10.1016/j.crmicr.2021.100022

Received 24 December 2020; Received in revised form 30 January 2021; Accepted 3 February 2021

2666-5174/© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

tality risk than patients with other cancer types (Antonio et al., 2020). An investigation that took place in China suggested that 18 out of 1590 cases of COVID-19 patients had a cancer history. Among these 18 patients, 5 patients had a history of lung cancer (28%). Another multicancer study in New York implied that 22 lung cancer patients (21%) were identified from 105 COVID-19 infected cancer patients (Dai et al., 2020). In both of the cases, lung cancer was found as the most frequent cancer type. In terms of fatality rate, a recent study in New York provides information that 6 out of 11 (55%) lung cancer patients died when infected by COVID-19 (Mehta et al., 2020, Landman et al., 2020).

If we scrutinize the overall pathophysiology of COVID-19, we will find that two proteins play a crucial role in the progression of the disease. The first one being the angiotensin-converting enzyme-2 (ACE2) receptor which mediates the SARS-CoV-2 virus's entry inside the host by letting the virus anchor using its envelope (Indwiani Astuti, 2020, Guo et al., 2020, Xu et al., 2020); the second once being cytokines which hallmark the entry of the pathogen by elucidating inflammatory signals. Previous studies have stated that the cytokine storm exacerbates the manifestations of SARS-CoV-2 inside the host through a sudden spike in its levels, triggering immune cells to rush in the site of inflammation and cause extensive tissue damage leading to subsequent development of Acute Respiratory Distress Syndrome (ARDS), multi-organ failure and ultimately death (Abassi et al., 2020, Routley, 2020, Barnes et al., 2020). Although at an initial stage the activated macrophages trigger the release of cytokines to the injured lung cells for resolving the inflammation, the release of pro-inflammatory signaling molecules once again increases the cytokine levels (Abassi et al., 2020, Routley, 2020, Barnes et al., 2020, Huang et al., 2020). These severe manifestations are amplified in patients with lung cancer, due to the preexisting elevated levels of ACE2 receptor, which facilitates the entry and localization of SARS-CoV-2 and cytokines (Feng et al., 2010, Zhang et al., 2020a,b, Qian et al., 2020). Recent reports claimed that C-X-C motif 10 (CXCL10), also known as Interferon gamma-induced protein 10 (IP-10) is one of the most crucial cytokines associated with COVID-19 disease severity (Yang et al., 2020). Moreover, studies have also drawn a conclusion to the fact that the CXCL10 pro-inflammatory chemokine is also associated with pathological processes like infectious diseases as well as cancers and cause significant tissue damage (Kanda et al., 2007, Lee et al., 2009). Hence, by analyzing both the ACE2 receptor and the CXCL10 chemokine in terms of expression, the nature of COVID-19 in lung cancer patients can be highlighted and understood at a comprehensive level and questions- why a certain cancer cohort is more susceptible to COVID-19 can be addressed.

In this *in silico* study, we analyzed ACE2 and CXCL10 in terms of expression pattern, functional characterization and mutation in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) to assess their possible involvement in the severe prognosis of COVID-19 in patients with lung cancer. We utilized existing cancer and expression databases and adapted protein-protein interaction network (PPIN) analysis schemas which currently is an effective method for scrutinizing the role of different proteins and genes in diseases and disorders at a molecular level. Because our analysis involved ACE2, CXCL10 and their coexpressed genes with regards to both healthy and lung cancer individuals, a clear comparison of the cohorts can help identify specific causes of COVID-19's clinical outcomes in lung cancer patients in regards to ACE2 and CXCL10 and can help in the proper management of COVID-19 in this cohort.

2. Materials and methodology

2.1. Expression analysis of the targeted genes

2.1.1. Analysis of gene expression in lung cancer

Data corresponding to ACE2 and CXCL10 mRNA expression patterns in lung cancer were retrieved from Tumor Immune Estimation Resource (TIMER) (http://cistrome.org/TIMER/). This tool allows a comprehensive analysis of the immune-suppressive nature of diverse cancer types. This web resource consists of six principal catalogs of analysis which allow to analyse gene expression data and their interconnections along with the immune-suppressed cancer cells (Li et al., 2017).

2.1.2. Extensive analysis of gene expression pattern in LUAD and LUSC

In-depth expression analysis of ACE2 and CXCL10 in LUAD and LUSC was done by using the TCGA data from the UALCAN web portal (http://ualcan.path.uab.edu/). This is a publicly accessible web plat-form that is frequently used to analyze the expression, co-expression of multiple genes, and their association with the clinical prognosis of variant cancer types by utilizing the TCGA data. UALCAN provides analytical data for 31 types of cancer (Chandrashekar et al., 2017).

2.1.3. Comparative analysis of the expression of targeted genes in LUAD and LUSC

Gene expression profiling interactive analysis (GEPIA) 2 database (http://gepia2.cancer-pku.cn/#index) is a web portal to analyze the mRNA expression of 8587 normal and 9736 tumor samples using the TCGA data. Besides the expression analysis, this database is also used for the gene-specific comparative analysis of different cancer types (Tang et al., 2019). Therefore, investigating the difference between ACE2 and CXCL10 expression in LUAD and LUSC was carried out by using the GEPIA 2 web portal.

2.2. Functional characterization of the targeted genes

2.2.1. Mutation and CNAs determination in the targeted proteins

Exploration of significant genetic changes in ACE2 and CXCL10 was done by using cBioPortal (https://www.cbioportal.org/). This software is an interactive web portal for systematic analysis of the multidisciplinary data sets of cancer genomics. Providing the data from more than 5000 tumor samples, this database is mostly used for the molecular profiling of cell lines and cancer tissue, mapping the frequency of mutations and other genetic alterations utilizing multidimensional cancer studies (Cerami et al., 2012).

2.2.2. Construction of protein-protein interaction network

Genes that are involved in COVID-19 development and predicted to have a dominant association with the viral disease were retrieved from the Comparative Toxicogenomics Database (CTD) (http://ctdbase.org/). CTD is a regularly updated database that delivers readily understandable records representing the gene-disease relationships (Mattingly et al., 2006). To analyze the interconnection between the proteins significantly associated with COVID-19, a network was generated among them by using the STRING software (https://string-db.org/). This software is mainly used to construct a protein-protein interaction network for showing multi-variant associations among the targeted proteins (Szklarczyk et al., 2017).

2.3. Co-expression analysis of the targeted genes

2.3.1. Identification of the co-expressed genes

The genes co-altered with the expression of ACE2 and CXCL10 in lung cancer were identified by using the R2: Genomics and Visualization platform (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). This database is an enriched resource of gene-specific datasets that allows to analyze, interpret, and reveal prominent outcomes of clinical research studies (Koster and Versteeg, 2008).

2.3.2. Determination of commonly co-expressed genes

The commonly co-altered genes of ACE2 and CXCL10 in both lung cancer and COVID-19 are determined by constructing the Venn diagrams using the Bioinformatics and Evolutionary Genomics (http://bioinformatics.psb.ugent.be/webtools/Venn/) web portal. The Venn diagram can generate a graphical output that represents the common elements of each listed intersection (Larran and Saeys, 2007).



Fig. 1. A schematic diagram representing the overall workflow of the study.

2.4. Interpretation of the functional role of the targeted genes

An integrative molecular assessment of the functional approaches of ACE2 and CXCL10 associated with the lung cancer and fatal type of COVID-19 development was attributed by using Protein Analysis Through Evolutionary Relationships (PAN-THER) (http://www.pantherdb.org/) tool. This is a comprehensive tool that can classify genes in terms of various attributes such as biological procedures, cellular structures, molecular attitudes, and pathways (Mi et al., 2013, Rahman et al., 2020) (Fig. 1).

3. Results

3.1. Expression of ACE2 and CXCL10 in lung cancer

Firstly, we analyzed the different expression patterns of ACE2 and CXCL10 in multidisciplinary cancer types using the TIMER database. Here, we found that ACE2 mRNA expression was significantly upregulated in lung adenocarcinoma (LUAD) (Fig. 2a). Also an increased level of expression in both LUAD and LUSC was shown by CXCL10 when compared to its normal tissues. *p*-value < 0.01 was evidenced in both the cancer types for CXCL10 (Fig. 2b). Overall, these results gave an indication of the overexpression of ACE2 and CXCL10 in LUAD and LUSC.



Fig. 2. The expression analysis of ACE2 and CXCL10 by using TIMER (a) Different level of ACE2 mRNA expression is shown in multiple cancer studies whereas the overexpression of ACE2 in LUAD and LUSC is marked in the red box (b) Different level of CXCL10 mRNA expression is shown in multiple cancer studies whereas the overexpression of CXCL10 in LUAD and LUSC is marked in the red box. *P*-value codes: *<0.05, **<0.01, ***<0.001 Abbreviation: LUAD- Lung Adenocarcinoma; LUSC- Lung squamous cell carcinoma

3.2. Analysis of ACE2 and CXCL10 expression pattern in LUAD and LUSC

We performed an extensive analysis to evaluate the association of ACE2 and CXCL10 expression with multiple clinicopathological parameters using the TCGA dataset retrieved from the UALCAN data mining platform. Here, we found an overall upregulated expression pattern of ACE2 in LUAD and LUSC compared to the normal condition based on individual cancer stages and different age groups. In terms of LUAD, the ACE2 expression level was found higher in all of the cancer stages where stage 4 shows the most elevated level compared to other cancer stages (Fig. 3a). Regarding LUSC, we found an increased level of ACE2 in all of the cancer stages except stage 4 (Fig. 3b). However, a similar kind of outcome representing the overexpression of ACE2 was observed in terms of variant age groups of the LUAD and LUSC patients. Among these age groups, ACE2 expression is most upregulated in the case of 61-80 years old patients. However, a slightly down-regulated expression of ACE2 was found for the age group of 41-60 years (Fig. 3c and d).

Next, we investigated the changes of CXCL10 expression based on different clinicopathological parameters. Here, we observed significant upregulation in CXCL10 expression in all cancer stages for both LUAD and LUSC patients. Among the four different cancer stages, the topmost elevated expression of CXCL10 was found in stage 2 for LUAD patients and stage 4 of LUSC patients (Fig. 3e and f). Besides the different cancer stages, we also found an elevated level of CXCL10 expression based on different age groups of LUAD and LUSC patients. Interestingly, CXCL10 expression was most upregulated in the younger age groups (21–40 years) compared to all other age groups of LUAD and LUSC (Fig. 3g and h).

After that, we generated an interactive heat map by using GEPIA 2 which compared the expression level of ACE2 and CXCL10 along with both cancer types, LUAD, and LUSC. This comparative illustration is represented based on the expression score of ACE2 and CXCL10. Both the genes showed a higher expression level in the tumor cells compared to the normal cells. However, ACE2 showed a higher expression score (1.4) in LUAD rather than the score (1.1) in LUSC. On the counterparts, CXCL10 showed a higher expression score (4.8) in LUSC than the score (4.5) in LUAD (Fig. 3i).

3.3. Analysis of genetic changes in ACE2 and CXCL10 protein sequences associated with lung cancer development

To evaluate the functional significance of ACE2 and CXCL10 in lung cancer development, we generated data representing multiple genetic alterations in ACE2 and CXCL10 mRNA using the cBioPortal database. Firstly, we prepared a query for ACE2 in this database using 6075 samples of 5719 lung cancer patients from 21 studies. From this analysis, we found out 64 mutations at 24 different locations of the 805 amino acids long human ACE2 protein (Table 1). Out of these 64 mutations, 51 were missense type, while the other 13 were recognized as truncated type (Fig 4a). After that, we extended our analysis to explore the frequency of genetic alterations in the ACE2 gene by using data from different lung cancer studies. Through this analysis, we observed that ACE2 is mostly altered in LUSC ranging the highest frequency of 3.49%. Though the alteration frequency fluctuated variously in multiple types of lung cancer studies, we managed to reveal that the least rate of alteration occurs in small cell lung cancer (Fig. 4b). Then, we focused on the expression level analysis of unique types of genetic alteration.



Fig. 3. Expression analysis of ACE2 and CXCL10 in lung cancer using the UALCAN database; (a) ACE2 gene expression in LUAD based on different cancer stages; (b) ACE2 gene expression in LUSC based on different cancer stages; (c) ACE2 gene expression in LUAD based on different age groups; (d) ACE2 gene expression in LUAD based on different age groups; (e) CXCL10 gene expression in LUAD based on different cancer stages; (g) CXCL10 gene expression in LUAD based on different age groups; (e) CXCL10 gene expression in LUAD based on different age groups; (b) CXCL10 gene expression in LUAD based on different age groups; (c) CXCL10 gene expression in LUAD based on different age groups; (c) CXCL10 gene expression in LUAD based on different age groups; (c) CXCL10 gene expression in LUAD based on different age groups; (b) CXCL10 gene expression in LUAD based on different age groups; (c) CXCL10 gene expression in LUAD based on the expression score in tumor tissues (T) and normal tissues (N).

Table 1

A list of genetic alternations in ACE2 protein sequences associated with lung cancer development.

Graduation Gravity 27 Final LUAD-800416 2012) 183 R768L Missence LUAD-800522 2012) R357 Missence LUAD-100722 Lung Adenocarcinoma (TCCA, 586 G211W Missence TCCA 44-7570-01 Lung Adenocarcinoma (MSKCC, Science 2015) 35 Missence TCCA 49-73488-01 Lung Adenocarcinoma (MSKCC, Science 2015) 35 Missence TCCA 49-73488-01 Lung Adenocarcinoma (MSKCC, Science 2015) 35 Missence TCCA 49-73488-01 Lung Adenocarcinoma (TCCA, 566 L220F Missence TCCA 49-7348-01 Lung Adenocarcinoma (TCCA, 566 L220F Missence TCCA 49-7348-01 Lung Adenocarcinoma (TCCA, 566 L220F Missence TCCA 49-7348-01 Lung Adenocarcinoma (TCCA, 230 G211W Missence TCCA 49-7348-01 Lung Adenocarcinoma (TCCA, 230 G211W Missence TCCA 49-7348-01 Lung Adenocarcinoma (TCCA, 230 G211W Missence TCCA 49-7348-01	Cancer study	Sample size	Protein change	Mutation type	Sample ID
Lung Ademocarcinoma (Broad, Cell 183 R7651. Missense LUAD-LIP77 2012) R57 Missense TCCA-45-7384-01 Lung Ademocarcinoma (TCCA, 586 C211W Missense TCCA-45-7394-01 Elichose Legacy) Bis CCA-44-2659-01 Bissense TCCA-45-7594-01 Lung Ademocarcinoma (MSKCC, Science 2015) 35 Nissense TCCA-45-75948-01 Japa Missense TCCA-45-75948-01 Bissense TCCA-45-75948-01 Japa CCA-45-75948-01 Bissense TCCA-45-75948-01 Bissense TCCA-45-75948-01 Japa Missense TCCA-45-75948-01 Bi			G747Wfs*27	FS ins	LUAD-B00416
2012) 857 Missense LUDP7 Lung Adenocarcinoma (TCGA, Firchose Legacy) 586 IZ36M Missense TCGA-457-346-01 Lung Adenocarcinoma (MSKCC, Science 2015) 586 G211W Missense TCGA-47-370-01 Lung Adenocarcinoma (MSKCC, Science 2015) 35 Missense TCGA-37-465-01 Lung Adenocarcinoma (MSKCC, Science 2015) 35 Missense TCGA-47-370-01 Lung Adenocarcinoma (TCGA, 566 1320F Missense TCGA-47-370-01 Lung Adenocarcinoma (TCGA, 566 1320F Missense TCGA-47-3780-01 Lung Adenocarcinoma (TCGA, 566 1320F Missense TCGA-57-3863-01 PanCancer Attas) T739P Missense TCGA-57-3863-01 Nature 2014) Missense TCGA-57-3863-01 Nature 2014) Missense TCGA-57-3863-01 Mater 2014) Missense TCGA-57-3863-01 Mater 2014) Missense TCGA-57-3863-01 Mater 2014) Missense TCGA-57-3683-01 Mater 2014) Missense TCGA-57-3683	Lung Adenocarcinoma (Broad, Cell	183	R768L	Missense	LUAD_E00522
Ling Adenocarcinoma (TCCA, 586 12.56M Missense TCCA.44-2659-01 Ling Adenocarcinoma (MSKCC, Science 2015) 35 N390K Missense TCCA.47-263-01 Lang Adenocarcinoma (MSKCC, Science 2015) 35 N390K Missense TCCA.43-738-01 Lang Adenocarcinoma (TCCA, 210 Missense TCCA.43-738-01 R199 Lang Adenocarcinoma (TCCA, 566 13.00 M Missense TCCA.44-7670-01 Racalcer Alas) 567 13.00 M Missense TCCA.44-7670-01 Racalcer Alas) Missense TCCA.44-7670-01 R199 Missense TCCA.447-670-01 Racalcer Alas) Missense TCCA.447-670-01 R199 Missense TCCA.425-850-01 Mature 2014) Missense TCCA.425-850-01 R219P Missense TCCA.425-850-01 Lang Adenocarcinoma (TCCA, 230 C211W Missense TCCA.425-850-01 Lang Adenocarcinoma (TCCA, 230 C211W Missense TCCA.425-801-01 Lang Adenocarcinoma (TCCA, 230 C211W Missense	2012)		R357	Missense	LUAD-LIP77
Lung Adenocarcinoma (TCCA, 586 6211 W Missense TCCA 44-7670-01 Firehose Legacy) 1320 F Missense TCCA 44-7670-01 Lung Adenocarcinoma (MSKCC, Science 2015) 35 N599K Missense TCCA 7-47465-01 Lung Adenocarcinoma (MSKCC, Science 2015) 35 N599K Missense TCCA 7-4746-01 Lung Adenocarcinoma (TCGA, 566 G211 W Missense TCCA 7-4768-01 Lang Adenocarcinoma (TCGA, 566 G211 W Missense TCCA 4-7670-01 Lang Adenocarcinoma (TCGA, 566 G210 W Missense TCCA 4-768-01 Pank Adenocarcinoma (TCGA, 230 Missense TCCA 4-768-01 Nature 2014) Missense TCCA 4-7670-01 12660 Mater 2014) Missense TCCA 4-7670-01 12660 Mature 2014) Missense TCCA 4-768-01 12660 Mater 2014) Missense TCCA 4-768-01 12660 Missense TCCA 4-768-01 1260 Missense TCCA 4-768-01 Mater 2014) Missense <			I256M	Missense	TCGA-95-7948-01
Lung Adenocarcinoma (TCCA, Firchose Legacy) S86 C211W Missense TCCA-48-789-01 Firchose Legacy) J200F Missense TCCA-48-789-01 Lung Adenocarcinoma (MSKCC, Science 2015) 35 N599K Missense FCCA-99-7458-01 Lung Adenocarcinoma (TCCA, ParCancer Atlas) 566 I220F Missense FCCA-49-7780-01 Lung Adenocarcinoma (TCCA, ParCancer Atlas) 566 I220F Missense TCCA-49-7780-01 Lung Adenocarcinoma (TCCA, ParCancer Atlas) 566 I220F Missense TCCA-97-788-01 Lung Adenocarcinoma (TCCA, ParCancer Atlas) 566 I220F Missense TCCA-57-7468-01 Missense TCCA-57-7468-01 TCCA-57-7468-01 TCCA-57-7468-01 Missense TCCA-57-7468-01 Mature 2014) Missense TCCA-47-70-01 Missense TCCA-47-70-01 Mature 2014) Missense TCCA-57-7468-01 Missense TCCA-57-7468-01 Mature 2014) Missense TCCA-47-70-01 Missense TCCA-47-70-01 Mature 2014) Missense TCCA-47-70-01 Missense			R219P	Missense	TCGA-44-2659-01
Firehose Legacy) L320F Missense TCCA-73-465-01 Lung Adenocarcinoma (MSKCC, Science 2015) 35 Missense TCCA-73-465-01 Lung Adenocarcinoma (MSKCC, Science 2015) 35 N599K Missense TCCA-73-465-01 Lung Adenocarcinoma (TCGA, 566 G211W Missense TCCA-47-708-01 Lang Adenocarcinoma (TCGA, 566 G211W Missense TCCA-47-708-01 Fancancer Atlas) Missense TCCA-47-708-01 Missense TCCA-47-708-01 Fang Adenocarcinoma (TCGA, 566 G211W Missense TCCA-47-708-01 Maser 2014) Missense TCCA-47-707-01 Missense TCCA-47-707-01 Mature 2014) Missense TCCA-47-70	Lung Adenocarcinoma (TCGA,	586	G211W	Missense	TCGA-44-7670-01
Degsn Missense TCCA-97-34638-01 Lung Adenocarcinoma (MSKCC, Science 2015) 35 N599K Missense FR347 Lung Adenocarcinoma (TCCA, 566 1200 Missense TCCA-97-7948-01 Lung Adenocarcinoma (TCCA, 566 1200 Missense TCCA-42-659-01 PanCancer Attas) 566 1200 Missense TCCA-42-659-01 PanCancer Attas) 799P Missense TCCA-42-659-01 PanCancer Attas) 799P Missense TCCA-42-659-01 PanCancer Attas) 799P Missense TCCA-42-659-01 Nature 2014) 1200 Missense TCCA-42-659-01 Attra 2014 1200 Missense TCCA-42-659-01 Lung Adenocarcinoma (TCCA, 20 C11W Missense TCCA-42-659-01 Lung Squamous Cell Carcinoma 511 V491L Missense TCCA-43-670-01 Lung Squamous Cell Carcinoma 718 V491L Missense TCCA-43-670-01 Lung Squamous Cell Carcinoma 718 C147V Missense	Firehose Legacy)		L320F	Missense	TCGA-69-7980-01
Hafw Missense TCR-95-748-01 Lung Adenocarcinoma (MSKCC, Science 2015) 35 N599K Missense TCGA-44-2650-01 Lung Adenocarcinoma (TCGA, 566 1320F Missense TCGA-44-2650-01 PanCancer Atlas) 1320F Missense TCGA-44-2650-01 PanCancer Atlas) 1320F Missense TCGA-49-734635-01 PanCancer Atlas) H34N Missense TCGA-97-9485-01 PanCancer Atlas) Wissense TCGA-97-9485-01 V670L Missense TCGA-97-9486-01 Nature 2014) Missense TCGA-97-9486-01 Lung Squamous Cell Carcinoma F11 V491 Missense TCGA-35-9350-01 Lung Squamous Cell Carcinoma F37 Y333.splice Splice TCGA-34-6770-01 Lung Squamous Cell Carcinoma F38 F147 Missense			D693N	Missense	TCGA-73-4658-01
Lung Adenocarcinoma (MSKCC, Science 2015) 35 N599K Missense TCGA-95-7948-01 R219P Missense TCGA-42-2659-01 G211W Missense TCGA-44-2659-01 G211W Missense TCGA-44-2659-01 G211W Missense TCGA-44-2659-01 CGA-95-7948-01 TCGA-95-7948-01 D693N Missense TCGA-45-2659-01 T795P Missense TCGA-55-8306-01 A995 Missense TCGA-55-8306-01 A995 Missense TCGA-55-8306-01 A995 Missense TCGA-45-7948-01 R219P Missense TCGA-47-7670-01 R219P Missense TCGA-47-7670-01 R219P Missense TCGA-47-7670-01 H34N Missense TCGA-97-34658-01 H34N Missense TCGA-97-34658-01 H34N Missense TCGA-97-734658-01 H34N Missense TCGA-97-734658-01 H34N Missense TCGA-97-734658-01 H34N Missense TCGA-97-734658-01 H34N Missense TCGA-97-734659-01 K1674 Missense TCGA-97-710-01 X233 splice Splice TCGA-36-7070-01 X233 splice Splice TCGA-35-7031-01 X195 splice Splice TCGA-35-6035-01 X233 splice Splice TCGA-35-6035-01 X233 splice Splice TCGA-35-7031-01 X195 splice Splice TCGA-35-703-01 X195 sp			H34N	Missense	TCGA-99-7458-01
Lung Adenocarcinoma (TCGA, 566 Nissense TCGA-44-2650-01 R219P Missense TCGA-44-2650-01 PanCancer Atlas) 1320F Missense TCGA-44-7670-01 PanCancer Atlas) Nissense TCGA-44-7670-01 TCGA-97-34658-01 H34N Missense TCGA-97-34658-01 TCGA-97-34658-01 H34N Missense TCGA-97-34658-01 TCGA-97-34658-01 H34N Missense TCGA-97-34658-01 TCGA-97-34658-01 Lung Adenocarcinoma (TCGA, 230 C211W Missense TCGA-47-2659-01 Lung Squamous Cell Carcinoma 511 V491L Missense TCGA-37-34658-01 Lung Squamous Cell Carcinoma 511 V491L Missense TCGA-37-34658-01 Lung Squamous Cell Carcinoma 487 Y333_splice Splice TCGA-34-3670-01 Lung Squamous Cell Carcinoma 178 G147V Missense TCGA-34-3670-01 Lung Squamous Cell Carcinoma 178 G147V Missense TCGA-34-3670-01 Lung Squamous Cell Carcinoma 178 G147V	Lung Adenocarcinoma (MSKCC, Science 2015)	35	N599K	Missense	FR9547
Lung Adenocarcinoma (TCGA, PanCancer Atlas) 566 G211W Missense TCCA-44-2659-01 PanCancer Atlas) 567 L320F Missense TCCA-97-368-01 PanCancer Atlas) Fight Missense TCCA-97-4658-01 PanCancer Atlas) Fight Missense TCCA-97-4658-01 Ung Adenocarcinoma (TCGA, Partice Contexpendence) Fight Missense TCCA-97-348-01 Lung Adenocarcinoma (TCGA, Nature 2014) 230 C211W Missense TCCA-47-2659-01 Lung Squamous Cell Carcinoma 511 C214W Missense TCCA-47-2658-01 Lung Squamous Cell Carcinoma 511 V491L Missense TCCA-47-368-01 Lung Squamous Cell Carcinoma 511 V491L Missense TCCA-47-368-01 Lung Squamous Cell Carcinoma 714 Wasense TCCA-47-369-01 Lung Squamous Cell Carcinoma 718 V491L Missense TCCA-43-570-01 V491L Missense TCCA-43-572-01 V491L Missense TCCA-43-572-01 Lung Squamous Cell Carcinoma 778 C31572 <td></td> <td></td> <td>I256M</td> <td>Missense</td> <td>TCGA-95-7948-01</td>			I256M	Missense	TCGA-95-7948-01
Lung Adenocarcinoma (TCGA, PanCancer Atlas) 566 L320/F Missense TCGA-47-7670-01 PanCancer Atlas) 566 L320/F Missense TCGA-97-458-01 PanCancer Atlas) H34N Missense TCGA-97-458-01 PanCancer Atlas) H34N Missense TCGA-97-458-01 Ung Adenocarcinoma (TCGA, Panchanger Adenocarcinoma (TCGA, Panchanger (MSK, Cancer Cell 2018) 75 Ya31s/2 F5 ins TCGA-43-4370-01 Lung Squamous Cell Carcinoma (TCGA, Nature 2012) 75 Ya33. spli			R219P	Missense	TCGA-44-2659-01
Lung Adenocarcinoma (LCA, PanCancer Atlas) PanCancer Atlas PanCancer PanCancer Atlas PanCancer PanCancer PanCancer PanCancer PanCancer PanCancer PanCancer PanCancer PanCancer PanCance		500	G211W	Missense	TCGA-44-7670-01
PanCancer Atlas) D93/4 Missense TCCA-97-468-01 H34M Missense TCCA-97-468-01 T798P Missense TCCA-97-468-01 Lung Adenocarcinoma (TCCA, 230 Raisense TCCA-97-2798-01 Lung Adenocarcinoma (TCCA, 230 C211W Missense TCCA-47-468-01 Lung Adenocarcinoma (TCCA, 230 C211W Missense TCCA-47-4707-01 Nature 2014) Lung Squamous Cell Carcinoma 511 V491L Missense TCCA-47-468-01 Lung Squamous Cell Carcinoma 511 V491L Missense TCCA-47-468-01 (TCCA, Firehose Legacy) X233 splice Splice TCCA-47-468-01 (TCCA, PanCancer Atlas) Y491L Missense TCCA-47-468-01 Lung Squamous Cell Carcinoma 487 Y631ks'2 F5 ins TCCA-47-405-401 Lung Squamous Cell Carcinoma 178 C417V Missense TCCA-47-50-501 Lung Squamous Cell Carcinoma 178 C417V Missense TCCA-47-50-501 Lung Squamous Cell Carcinoma 178	Lung Adenocarcinoma (ICGA,	566	L320F	Missense	ICGA-69-7980-01
H34N Missense TCA-39-748-01 T738 Missense TCA-55-8205-01 V670L Missense TCA-55-8205-01 V670L Missense TCA-55-8205-01 Lung Adenocarcinoma (TCCA, 230 C211W Missense TCA-42-859-01 Nature 2014) L206 Missense TCA-44-7670-01 Nature 2014) Missense TCA-44-7670-01 Ung Squamous Cell Carcinoma 511 V491L Missense TCA-69-7980-01 (TCCA, Firehose Legacy) C317V Missense TCA-43-6770-01 (TCCA, Firehose Legacy) V491L Missense TCA-43-6770-01 (TCGA, Firehose Legacy) V431E Missense TCA-43-6770-01 (TCGA, Firehose Legacy) V331s/2 F5 ins TCA-43-6770-01 (TCGA, Anacancer Atlas) V331s/2 F3 ins TCA-43-6770-01 Lung Squamous Cell Carcinoma 178 C147V Missense TCA-43-6770-01 Lung Squamous Cell Carcinoma 178 C147V Missense TCA-43-6770-01 Lung Squamous Cell Ca	PanCancer Atlas)		D693N	Missense	ICGA-73-4658-01
17987 Missense TCA-33-8206-01 V670L Missense TCA-58-8506-01 499S Missense TCA-62-A48R-01 Lung Adenocarcinoma (TCCA, 230 C211W Missense TCA-42-859-01 Lung Squamous Cell Carcinoma 230 C211W Missense TCA-44-2639-01 Lung Squamous Cell Carcinoma 511 V491L Missense TCA-69-7988-01 Lung Squamous Cell Carcinoma 511 V491L Missense TCA-39-5035-01 (TCCA, Firehose Legacy) C147V Missense TCCA-39-5035-01 V331Le Splice TCCA-39-5035-01 (TCCA, Firehose Legacy) C147V Missense TCCA-39-5035-01 (TCCA, Anaccer Atlas) C331Sr2 P5 ins TCCA-39-5035-01 (TCGA, PanCancer Atlas) C333 Splice TCCA-34-677-01 (TCCA, Anare 2012) Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 Nissense TCCA-21-016-01 Lung Squamous Cell Carcinoma 178 C147V Missense TCCA-22-1016-01 Lung Squamous Cell Carcinoma <td< td=""><td></td><td></td><td>H34N</td><td>Missense</td><td>ICGA-99-7458-01</td></td<>			H34N	Missense	ICGA-99-7458-01
V0/0.1 Missense TCA-32-300-01 Lung Adenocarcinoma (TCCA, Nature 2014) 230 Kissense TCA-42-K69.01 Nature 2014) G211W Missense TCA-42-K69.01 Nature 2014) D693 Missense TCA-44-7670-01 Nature 2014) Missense TCA-42-K69-7980-01 D693 Missense TCA-69-7988-01 Lung Squamous Cell Carcinoma 511 V491L Missense TCA-39-638-01 (TCCA, Firehose Legacy) C147V Missense TCA-39-635-01 (TCGA, Firehose Legacy) C147V Missense TCA-39-5035-01 (TCGA, Firehose Legacy) X233_splice Splice TCA-43-6770-01 Lung Squamous Cell Carcinoma 487 Y633Isr2 F5 ins TCA-39-5035-01 (TCGA, Fancancer Atlas) Y777 Missense TCA-34-637-71-01 Ung Squamous Cell Carcinoma 178 C147V Missense TCA-39-5035-01 (TCGA, Ature 2012) Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195-splice Splice TCA-44-677-01 Non-Sm			1798P	Missense	TCGA-55-8205-01
Lung Adenocarcinoma (TCGA, Nature 2014) 230 Missense R219P Missense Missense TCGA-43-57348-01 Lung Squamous Cell Carcinoma 230 Call W Missense TCGA-43-570-01 Lung Squamous Cell Carcinoma 511 V491L Missense TCGA-43-670-01 (TCGA, Firehose Legacy) 511 V491L Missense TCGA-39-7458-01 (TCGA, Firehose Legacy) C147V Missense TCGA-39-7458-01 (TCGA, Firehose Legacy) C147V Missense TCGA-39-7458-01 (TCGA, Firehose Legacy) C147V Missense TCGA-39-7503-01 X233_splice Splice TCGA-39-5035-01 X233_splice (TCGA, PanCancer Atlas) Y633L572 FS ins TCGA-39-5703-01 (TCGA, PanCancer Atlas) Y635_Splice TCGA-39-570-01 (TCGA, Nature 2012) TCGA 30-5035-01 X233_splice Splice TCGA-39-770-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice TCGA-39-570-01 Nun-Small Cell Lung Cancer (TCGA, Nat FCGA-39-570-01 X233_splice Splice <			V0/UL	Missense	TCGA-55-6500-01
Lung Adenocarcinoma (TCGA, Nature 2014) Hissense 230 TCGA-44-2658-01 C211W Missense Missense TCGA-44-2658-01 TCGA-44-2658-01 hature 2014) Missense TCGA-44-7670-01 Missense TCGA-44-2658-01 hung Squamous Cell Carcinoma 511 V491L Missense TCGA-37-3658-01 (TCGA, Firehose Legacy) CIA7V Missense TCGA-47-2658-01 (TCGA, Firehose Legacy) CIA7V Missense TCGA-37-4583-01 (TCGA, Firehose Legacy) CIA7V Missense TCGA-47-2658-01 (TCGA, Firehose Legacy) CIA7V Missense TCGA-37-4585-01 (TCGA, PanCancer Atlas) CIA7V Missense TCGA-43-6578-01 (TCGA, PanCancer Atlas) C395V Missense TCGA-34-6578-01 (TCGA, Nature 2012) TCGA-412-01 Missense TCGA-43-6578-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice TCGA-43-6770-01 Numesense TCGA-43-6770-01 X233_splice Splice TCGA-43-6770-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X233_splice			A995 1256M	Missense	TCGA-02-A40R-01
Lung Adenocarcinoma (TCGA, Nature 2014) 230 G211W Missense TCGA-44-7670-01 1320F Missense TCGA-44-7670-01 1320F Missense TCGA-49-7880-01 D693 Missense TCGA-97-868-01 H34N Missense TCGA-97-458-01 Lung Squamous Cell Carcinoma (TCGA, Firehose Legacy) 511 V491L Missense TCGA-39-658-01 V491L Missense TCGA-39-658-01 V491L Missense TCGA-39-6780-01 V491L Missense TCGA-39-6780-01 V491L Missense TCGA-39-6780-01 V491L Missense TCGA-39-6780-01 V491L Missense TCGA-39-6780-01 V491L Missense TCGA-39-6780-01 (TCGA, PanCancer Atlas) (TCGA, PanCancer Atlas) Ung Squamous Cell Carcinoma (TCGA, PanCancer Atlas) Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) Pan-Lung Cancer (TCGA, Nat Genet 2016) Pan-Lung Cancer (TCGA, Nat Genet 2016) Pan-Lung Cancer (TCGA, Nat Genet 2016) Pan-Lung Cancer (TCGA, Nat Genet 2016) Non-Small Cell Lung Cancer (TCGA, Nat Genet 2017) Non-Small Cell L			R219P	Missense	TCCA-44-2659-01
Nature 2014) Low Low Lasting Low Missense TCGA-69-7980-01 Nature 2014) D693 Missense TCGA-69-7980-01 Lung Squamous Cell Carcinoma 511 V491L Missense TCGA-97-4658-01 (TCGA, Firehose Legacy) V491L Missense TCGA-93-5035-01 X233_splice Splice TCGA-43-6770-01 V491L Missense TCGA-39-5035-01 X233_splice Splice TCGA-43-6770-01 V491L Missense TCGA-39-5035-01 X233_splice Splice TCGA-34-86710-01 C147V Missense TCGA-34-8670-01 V491L Missense TCGA-32-3487-01 (TCGA, PanCancer Atlas) V477R Missense TCGA-32-3741-01 V477R Missense TCGA-32-734-01 X195_splice TCGA-32-3053-01 Lung Squamous Cell Carcinoma 178 C147V Missense TCGA-34-670-01 Lung Squamous Cell Carcinoma 178 C147V Missense TCGA-43-670-01 Lung Squamous Cell Carcinoma<	Lung Adenocarcinoma (TCCA	230	G211W	Missense	TCGA-44-7670-01
Instruction () D693 Missense TCGA-73-4658-01 Lung Squamous Cell Carcinoma 511 Walk Missense TCGA-39-5035-01 (TCGA, Firehose Legacy) C147V Missense TCGA-39-5035-01 (TCGA, Firehose Legacy) C147V Missense TCGA-39-5035-01 (TCGA, PanCancer Atlas) C147V Missense TCGA-39-5035-01 (TCGA, PanCancer Atlas) C233_splice Splice TCGA-33-4587-01 (TCGA, PanCancer Atlas) C395V Missense TCGA-33-4587-01 (TCGA, PanCancer Atlas) C395V Missense TCGA-33-4587-01 (TCGA, PanCancer Atlas) TCGA-22-1016-01 Missense TCGA-33-4582-01 (TCGA, PanCancer Atlas) TCGA-30-532-01 X195_splice Splice TCGA-39-5035-01 (TCGA, Nature 2012) X195_splice Splice TCGA-39-5035-01 X23-splice Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice TCGA-39-5035-01 R768L Missense TCGA-39-5035-01 X23-splice Splice TCGA-39-7948-01	Nature 2014)	250	L320F	Missense	TCGA-69-7980-01
H3AN Missense TCGA-99-7458-01 Lung Squamous Cell Carcinoma 511 V491L Missense TCGA-22-1016-01 (TCGA, Firehose Legacy) X233_splice Splice TCGA-39-5035-01 X233_splice Splice TCGA-43-6770-01 Lung Squamous Cell Carcinoma 487 Y633Lfs-2 F5 ins TCGA-39-5035-01 Lung Squamous Cell Carcinoma 487 Y633Lfs-2 F5 ins TCGA-39-5035-01 (TCGA, PanCancer Atlas) X233_splice Splice TCGA-39-5035-01 (TCGA, PanCancer Atlas) Y477R Missense TCGA-39-5035-01 Lung Squamous Cell Carcinoma 178 C147V Missense TCGA-39-5035-01 Lung Squamous Cell Carcinoma 178 C147V Missense TCGA-39-5035-01 Lung Squamous Cell Carcinoma 178 C147V Missense TCGA-39-5035-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice TCGA-39-5035-01 G256M Missense TCGA-42-657-01 Splice TCGA-42-657-01 Q174/S*27	Hatare 2011)		D693	Missense	TCGA-73-4658-01
Lung Squamous Cell Carcinoma 511 V4911 Missense TCGA-22-1016-01 (TCGA, Firehose Legacy) G147 Missense TCGA-39-5035-01 X233_splice Splice TCGA-39-5035-01 V4911 Missense TCGA-39-5035-01 V4911 Missense TCGA-39-5035-01 V233_splice Splice TCGA-39-5035-01 Lung Squamous Cell Carcinoma 487 G395V Missense TCGA-43-6770-01 Lung Squamous Cell Carcinoma 487 G395V Missense TCGA-93-548-01 (TCGA, PanCancer Atlas) TCGA G395V Missense TCGA-93-697-01 Lung Squamous Cell Carcinoma 178 C147V Missense TCGA-93-9035-01 (TCGA, Nature 2012) X195_splice Splice TCGA-43-6770-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice TCGA-43-6770-01 1230F Missense TCGA-43-6770-01 Li20F Missense TCGA-43-6770-01 1230F Missense TCGA-44-2659-01 G211W Missense			H34N	Missense	TCGA-99-7458-01
(TCGA, Firehose Legacy) G147V Missense TCGA-39-5035-01 X233_splice Splice TCGA-43-6770-01 Ung Squamous Cell Carcinoma 487 Y633Lfs*2 FS ins TCGA-34-6770-01 Lung Squamous Cell Carcinoma 487 Y633Lfs*2 FS ins TCGA-34-36770-01 (TCGA, PanCancer Atlas) W477R Missense TCGA-34-3770-01 (TCGA, PanCancer Atlas) W477R Missense TCGA-32-731-01 (TCGA, Nature 2012) W477R Missense TCGA-34-3524-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 C147V Missense TCGA-43-6770-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice nsclc_mskcc_2018s50 C147V Missense TCGA-43-679-01 X233_splice Splice nscl_mskc-2018s50 Pan-Lung Cancer (TCGA, Nature 2012) 75 X195_splice Splice TCGA-44-659-01 G210W Missense TCGA-44-659-01 L320F Missense TCGA-43-677-01 Pan-Lung Cancer (TCGA, Nat T144 Y633Lfs*12	Lung Squamous Cell Carcinoma	511	V491L	Missense	TCGA-22-1016-01
X23_splice Splice TCGA-43-6770-01 V491L Missense TCGA-22-1016-01 Lung Squamous Cell Carcinoma 487 Y632 Splice TCGA-33-5035-01 (TCGA, PanCancer Atlas) Y633 Fslins TCGA-33-5035-01 (TCGA, PanCancer Atlas) Y633 Fslins TCGA-33-5035-01 (TCGA, PanCancer Atlas) Y633 Fslins TCGA-33-532-01 (TCGA, PanCancer Atlas) Y633 Fslins TCGA-33-532-01 (TCGA, Alarce 2012) X195 Splice TCGA-22-1016-01 Lung Squamous Cell Carcinoma 178 X195 Splice TCGA-35-5035-01 (TCGA, Nature 2012) X195 Splice Scl.cmskcc.2018s50 TCGA-43-6770-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195 Splice Scl.cmskcc.2018s50 TCGA-44-2670 TCGA-44-2670-01 TCGA-44-2650-01 G747WIs*27 FS ins LUAD.E00522-Tumor R768L Missense TCGA-43-6770-01 TCGA-43-6770-01 TCGA-43-6770-01 Luap Lung Cancer (TCGA, Nat T144 Y63	(TCGA, Firehose Legacy)		G147V	Missense	TCGA-39-5035-01
V491L Missense TCGA-22-1016-01 Lung Squamous Cell Carcinoma 487 Y633L5'2 FS ins TCGA-33-635-01 (TCGA, PanCancer Atlas) Y633L5'2 FS ins TCGA-33-6770-01 W477R Missense TCGA-37-6771-01 W477R Missense TCGA-22-1016-01 Lung Squamous Cell Carcinoma 178 C147V_splice Splice TCGA-22-7016-01 Lung Squamous Cell Carcinoma 178 C147V Missense TCGA-22-1016-01 Lung Squamous Cell Carcinoma 178 C147V Missense TCGA-33-6350-01 (TCGA, Nature 2012) X33_splice Splice TCGA-43-6770-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice TCGA-43-6770-01 R768L Missense TCGA-43-6770-01 C3147W Mis 27 FS ins LUAD-E00322-Tumor R219P Missense TCGA-43-6770-01 L320F Missense TCGA-43-6770-01 Cartor Missense TCGA-43-6770-01 L320F Missense TCGA-43-6770-01 Gartor Missense			X233_splice	Splice	TCGA-43-6770-01
Lung Squamous Cell Carcinoma 487 K323_splice Splice TCCA-39-5035-01 Lung Squamous Cell Carcinoma 487 Y633LIs'2 FS ins TCCA-34-5770-01 (TCCA, PanCancer Atlas) W377R Missense TCCA-34-567731-01 W477R Missense TCCA-34-502-7341-01 X195_splice Splice TCCA-34-5035-01 V491L Missense TCCA-39-5035-01 X195_splice Splice TCCA-39-5035-01 V491L Missense TCCA-39-5035-01 X233_splice Splice TCCA-43-6770-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice TCCA-43-6708-01 R768L Missense TCCA-43-6707-01 Missense TCCA-43-6707-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice Missense TCCA-43-6707-01 R260 Missense TCCA-43-6707-01 Missense TCCA-43-6707-01 R210P Missense TCCA-43-6707-01 Missense TCCA-43-6707-01 R210P M			V491L	Missense	TCGA-22-1016-01
Lung Squamous Cell Carcinoma 487 X233_splice Splice TCGA-33-6770-01 (TCCA, PanCancer Atlas) V6331fs*2 F5 ins TCGA-33-4587-01 (TCCA, PanCancer Atlas) W477R Missense TCGA-32-731-01 W477R Missense TCGA-22-731-01 V491L Missense TCGA-22-731-01 V491L Missense TCGA-22-731-01 V491L Missense TCGA-22-731-01 V195_splice Splice TCGA-22-1016-01 Lung Squamous Cell Carcinoma 178 C147V Missense TCGA-39-5035-01 (TCCA, Natrue 2012) X195_splice Splice nsclc_mskcc_2018s50 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice TCGA-43-6770-01 R768L Missense TCGA-44-2659-01 C211W Missense TCGA-49-7850-01 I320F Missense TCGA-43-6770-01 H34N Missense TCGA-43-6770-01 Pan-Lung Cancer (TCGA, Nat 1144 K633Lfs*2 F5 ins TCGA-43-6773-01 C147V <			G147V	Missense	TCGA-39-5035-01
Lung Squamous Cell Carcinoma 487 Y633Lfs*2 F5 ins TCCA-33-4587-01 (TCGA, PanCancer Atlas) G395V Missense TCGA-36-7731-01 W477R Missense TCGA-36-7731-01 W477R Missense TCGA-34-524-01 V491L Missense TCGA-22-7341-01 V491L Missense TCGA-23-5035-01 (TCGA, Nature 2012) X195_splice Splice TSCL-38-57048-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice TSCL-38-7948-01 G747Wfs*27 FS ins LUAD_B00522-Tumor R766L Missense TCGA-43-6770-01 Missense TCGA-44-2659-01 G211W Missense TCGA-44-2659-01 G211W Missense TCGA-43-7670-01 L320F Missense TCGA-43-7670-01 H34N Missense TCGA-43-7670-01 L320F Missense TCGA-35-820-01 G211W Missense TCGA-33-4587-01 Missense TCGA-35-7348-01 K233_splice Splice TCGA-35-7348-01 Missense			X233_splice	Splice	TCGA-43-6770-01
(TCGA, PanCancer Atlas) G395V Missense TCGA-56-7731-01 W477R Missense TCGA-22-7016-01 Lung Squamous Cell Carcinoma 178 C147V Missense TCGA-22-1016-01 (TCGA, Nature 2012) X233_splice Splice TCGA-43-6770-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice nsc.2 nsc.2 Nsc.2 R768L Missense TCGA-43-6770-01 Nsc.2 Nsc.2 <td>Lung Squamous Cell Carcinoma</td> <td>487</td> <td>Y633Lfs*2</td> <td>FS ins</td> <td>TCGA-33-4587-01</td>	Lung Squamous Cell Carcinoma	487	Y633Lfs*2	FS ins	TCGA-33-4587-01
W477R Missense TCGA-92-7341-01 X195_splice Splice TCGA-13-A524-01 V491L Missense TCGA-22-1016-01 (TCGA, Nature 2012) X233_splice Splice TCGA-39-5035-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice nsicn_mskcc_2018550 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice ncGA-43-6770-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice ncGA-43-6770-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice TCGA-43-670-01 RCR68L Missense TCGA-44-2659-01 C211W Missense TCGA-42-659-01 Lung Cancer (TCGA, Nat 1144 Y633Lfsr2 FS ins TCGA-33-4587-01 Cancer (TCGA, Nat 1144 Y633Lfsr2 FS ins TCGA-43-6770-01 Cancer (TCGA, Nat 1144 Y633Lfsr2 FS ins TCGA-43-6770-01 Cancer (TCGA, Nat 1144 Y633Lfsr2 FS ins TCGA-43-6770-01	(TCGA, PanCancer Atlas)		G395V	Missense	TCGA-56-7731-01
X195_spice Spice TCGA-13-A524-01 Lung Squamous Cell Carcinoma 178 G147V Missense TCGA-22-1016-01 (TCGA, Nature 2012) X233_splice Splice TCGA-43-6770-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice nsclskcc2018:50 1256M Missense TCGA-43-6770-01 R768L Missense TCGA-44-2659-01 C747Wfs"27 FS ins LUAD-B00416-Tumor R768L Missense TCGA-44-2659-01 C211W Missense TCGA-44-2659-01 G211W Missense TCGA-44-2659-01 L320F Missense TCGA-43-6770-01 L320F Missense TCGA-43-6770-01 L320F Missense TCGA-43-6770-01 L320F Missense TCGA-43-6770-01 Pan-Lung Cancer (TCGA, Nat 1144 Y633Lfs'2 FS ins TCGA-33-4587-01 Gases Missense TCGA-58-205-01 W670L Missense TCGA-58-205-01 Gases Missense TCGA-58-205-01 K670L Missense TCGA-58-205-			W477R	Missense	TCGA-92-7341-01
Van Missense TCCA-22-1016-01 Lung Squamous Cell Carcinoma 178 G147V Missense TCCA-39-5035-01 (TCCA, Nature 2012) X233_splice Splice TCCA-43-6770-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice nscl_mskc_2018s50 I256M Missense TCCA-43-6770-01 G7477WIs*27 F5 ins LUAD_B00416-Tumor R768L Missense TCCA-44-7670-01 G7477WIs*27 F5 ins LUAD_B00522-Tumor R219P Missense TCCA-44-7670-01 G147V Missense TCCA-44-7670-01 L320F Missense TCCA-43-670-01 G147V Missense TCCA-39-5035-01 V491L Missense TCCA-43-670-01 G147V Missense TCCA-39-5035-01 V491L Missense TCCA-39-5035-01 X23_splice Splice TCCA-43-670-01 Genet 2016) TY491L Missense TCCA-43-670-01 X23_splice Splice TCCA-55-8205-01 Genet 2016) TY98P Missense TCCA-55-8205-01<			X195_splice	Splice	TCGA-L3-A524-01
Lung Squamous Cell Carcinoma 178 G147V Missense 1CGA-39-5035-01 (TCGA, Nature 2012) X233_splice Splice TCGA-43-6770-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195_splice Splice nsclc_mskcc_2018s50 IZ56M Missense TCGA-43-6770-01 IX95_splice Splice nsclc_mskcc_2018s50 IZ56M Missense TCGA-44-2659-01 G747Wfs*27 FS ins LUAD-B00416-Tumor R219P Missense TCGA-44-2659-01 G211W Missense TCGA-44-7670-01 L320F Missense TCGA-44-7670-01 L320F Missense TCGA-43-6770-01 H34N Missense TCGA-43-6770-01 L320F Missense TCGA-43-6770-01 Y233_splice Splice Splice TCGA-43-6770-01 Y233_splice Splice TCGA-43-6770-01 Pan-Lung Cancer (TCGA, Nat 1144 Y633Lfs*2 FS ins TCGA-33-4587-01 G335 Genet 2016) T798P Missense TCGA-55-7548-01 G335 Missense TCGA-52-746R-01		170	V491L	Missense	TCGA-22-1016-01
(TCCA, Nature 2012) X139 Splice Splice 1CCA-43-67/10-01 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X135_splice Splice nscl_mskc, 2018s50 [256M Missense TCGA-95-7948-01 G747Wfs*27 FS ins LUAD_B00416-Tumor R768L Missense TCGA-42-659-01 G211W Missense TCGA-42-659-01 G211W Missense TCGA-42-659-01 G211W Missense TCGA-97458-01 Pan-Lung Cancer (TCGA, Nat 1144 Missense TCGA-43-6770-01 X233_splice Splice TCGA-33-5035-01 Pan-Lung Cancer (TCGA, Nat 1144 Y633Lfs*2 FS ins TCGA-33-5035-01 X233_splice Splice TCGA-55-8205-01 Genet 2016) T798P Missense TCGA-55-8205-01 V670L Missense TCGA-55-8506-01 G395 Missense TCGA-55-8205-01 V670L Missense TCGA-51-8520-01 V670L Missense TCGA-55-8505-01 Missense TCGA-52-731-01 A99S Missense TCGA-51-850-01 Missense TCGA-23-4524-01 R3575 Missense T	Lung Squamous Cell Carcinoma	178	GI4/V	Missense	ICGA-39-5035-01
Non-Shial Cell Lung Cancer (MSK, Cancer Cell 2018) 75 X195 X195 Spince Instell Lung Cancer R768L Missense LUAD_B00416-Tumor R768L Missense LUAD_B00522-Tumor R219P Missense TCGA-95-7948-01 G211W Missense TCGA-44-2659-01 G211W Missense TCGA-99-7458-01 L320F Missense TCGA-99-7458-01 H34N Missense TCGA-99-7458-01 V491L Missense TCGA-99-7458-01 V491L Missense TCGA-99-7458-01 V491L Missense TCGA-99-7458-01 V491L Missense TCGA-99-7458-01 V233_splice Splice TCGA-43-55035-01 V233_splice Splice TCGA-55-8205-01 V670L Missense TCGA-55-8205-01 G395 Missense TCGA-55-8205-01 G395 Missense TCGA-62-A46R-01 W477R Missense TCGA-62-A46R-01 W477R Missense CUK0001-R1 Non-S	(ICGA, NATURE 2012)	75	X233_splice	Splice	ICGA-43-6770-01
Pan-Lung Cancer (TCGA, Nat 1144 YG32Lfs² FS ins LUAD-B00416-Tumor Pan-Lung Cancer (TCGA, Nat 1144 Kasappi (Kasappi) Missense TCGA-44-2659-01 G211W Missense TCGA-44-2659-01 12320F Missense TCGA-44-2659-01 G211W Missense TCGA-44-2659-01 12320F Missense TCGA-499-7458-01 H34N Missense TCGA-499-7458-01 13320F Missense TCGA-39-7458-01 V491L Missense TCGA-39-7458-01 1434 Missense TCGA-39-5035-01 V491L Missense TCGA-39-5035-01 1233_splice Splice TCGA-43-6770-01 Genet 2016) T798P Missense TCGA-58-8205-01 144 Y633Lfs²2 FS Nissense TCGA-58-731-01 Ga95 Missense TCGA-69-7341-01 144 Y635 Missense TCGA-62-7341-01 X195_splice Splice TCGA-64-761-01 X195_splice Splice TCGA-62-7341-01 X195_splice Splice TCGA-62-7341-01 X	Non-Sman Cen Lung Cancer (MSK, Cancer Cen 2018)	/5	X195_splice	Splice	TCCA 05 7048 01
Pan-Lung Cancer (TCGA, Nat 1144 1144 Korking 27 15 ms ED/05/2010/101 Pan-Lung Cancer (TCGA, Nat 1144 1144 Missense TCGA-44-2659-01 Pan-Lung Cancer (TCGA, Nat 1144 Missense TCGA-44-2659-01 Genet 2016) V491L Missense TCGA-49-7980-01 Pan-Lung Cancer (TCGA, Nat 1144 Y633Lfs*2 FS ins TCGA-39-5035-01 Cenet 2016) V491L Missense TCGA-39-5035-01 Pan-Lung Cancer (TCGA, Nat 1144 Y633Lfs*2 FS ins TCGA-43-6770-01 Genet 2016) T798P Missense TCGA-55-8205-01 V670L Missense TCGA-55-8205-01 V670L Missense TCGA-56-7731-01 A99S Missense TCGA-22-7341-01 V4977R Missense TCGA-23-A524-01 R357S Missense TCGA-23-A524-01 Non-Small Cell Lung Cancer 447 A403V Missense CRUK0001-R1 (TRACERx, NEJM & Nature 2017) 447 A403V Missense CRUK0001-R2 K676E <			C747W/fs*27	FS inc	IUAD-800/16-Tumor
R219P Missense TCGA-44-2659-01 G211W Missense TCGA-44-2659-01 G211W Missense TCGA-44-2659-01 G211W Missense TCGA-49-7980-01 L320F Missense TCGA-99-7458-01 V491L Missense TCGA-22-1016-01 G147V Missense TCGA-39-503-01 X233_splice Splice TCGA-39-503-01 K233_splice Splice TCGA-33-4587-01 Genet 2016) 1144 Y633Lfs*2 FS ins TCGA-55-8205-01 Genet 2016) 7798P Missense TCGA-55-8506-01 G395 Missense TCGA-55-8506-01 6395 G395 Missense TCGA-62-7446R-01 W477R Missense TCGA-52-731-01 A99S Missense TCGA-13-A524-01 Non-Small Cell Lung Cancer 447 A403V Missense CRUK0001-R1 Non-Small Cell Lung Cancer 447 A403V Missense CRUK0001-R3 (TRACERx, NEJM & Nature 2017) A403V Missense CRUK0001-R3 K676E Missense S5208<			R768I	Missense	LUAD F00522-Tumor
Ratio Rustin Rustin </td <td></td> <td></td> <td>R700E R219P</td> <td>Missense</td> <td>TCGA-44-2659-01</td>			R700E R219P	Missense	TCGA-44-2659-01
Pan-Lung Cancer (TCGA, Nat 1144 1144 Y491L Missense TCGA-69-7980-01 Pan-Lung Cancer (TCGA, Nat 1144 Y633Lfs*2 FS ins TCGA-39-5035-01 Genet 2016) X233_splice Splice TCGA-39-5035-01 V491L Missense TCGA-39-5035-01 K233_splice Splice TCGA-39-5035-01 K233_splice Splice TCGA-33-5035-01 K233_splice Splice TCGA-33-5035-01 K233_splice Splice TCGA-43-6770-01 K33Lfs*2 FS ins TCGA-55-8205-01 V670L Missense TCGA-55-8205-01 V670L Missense TCGA-62-A46R-01 W477R Missense TCGA-92-7341-01 X195_splice Splice TCGA-13-4524-01 K357S Missense CRUK0001-R1 Non-Small Cell Lung Cancer 447 A403V Missense CRUK0001-R2 (TRACERx, NEJM & Nature 2017) 447 A403V Missense CRUK0001-R3 K676E Missense CRUK0001-R3 <t< td=""><td></td><td></td><td>G211W</td><td>Missense</td><td>TCGA-44-7670-01</td></t<>			G211W	Missense	TCGA-44-7670-01
Pan-Lung Cancer (TCGA, Nat 1144 H34N Missense TCGA-99-7458-01 Pan-Lung Cancer (TCGA, Nat 1144 Y633Lfs*2 Splice TCGA-39-5035-01 Senet 2016) X233_splice Splice TCGA-39-5035-01 Pan-Lung Cancer (TCGA, Nat 1144 Y633Lfs*2 FS ins TCGA-33-4587-01 Genet 2016) 1144 Y633Lfs*2 FS ins TCGA-33-4587-01 Genet 2016) 1144 Y633Lfs*2 FS ins TCGA-35-8205-01 V670L Missense TCGA-55-8205-01 G395 Missense TCGA-56-7731-01 A99S Missense TCGA-62-A46R-01 W477R Missense TCGA-22-7341-01 X195_splice Splice TCGA-104-104 X195_splice Splice TCGA-104-104 Non-Small Cell Lung Cancer 447 A403V Missense CRUK0001-R1 Non-Small Cell Lung Cancer 447 A403V Missense CRUK0001-R3 K676E Missense CRUK0001-R3 K676E Missense CRUK0027-R2 E398K Missense S5208 Small Cell Lung Cancer (Johns 80 K632_splice			L320F	Missense	TCGA-69-7980-01
V491L Missense TCGA-22-1016-01 G147V Missense TCGA-39-5035-01 X233_splice Splice TCGA-43-6770-01 Pan-Lung Cancer (TCGA, Nat 1144 Y633Lfs*2 FS ins TCGA-33-4587-01 Genet 2016) T798P Missense TCGA-55-8205-01 V670L V670L Missense TCGA-55-8205-01 V670L Missense TCGA-56-7731-01 A99S Missense TCGA-62-A46R-01 V497R Missense TCGA-22-7341-01 X195_splice Splice TCGA-55-8205-01 V497R Missense TCGA-52-406R-01 Non-Small Cell Lung Cancer 447 A403V Missense CRUK0001-R1 Non-Small Cell Lung Cancer 447 A403V Missense CRUK0001-R2 (TRACERx, NEJM & Nature 2017) 447 A403V Missense CRUK0001-R3 K676E Missense CRUK0001-R3 K676E Missense S5208 Small Cell Lung Cancer (Johns 80 X632_splice Splice sclc_ucologne_2015_S02093 Ho			H34N	Missense	TCGA-99-7458-01
G147V Missense TCGA-39-5035-01 Pan-Lung Cancer (TCGA, Nat 1144 YG33Lfs*2 FS ins TCGA-33-4587-01 Genet 2016) T798P Missense TCGA-55-8506-01 G395 Gays Missense TCGA-65-7731-01 A99S Missense TCGA-62-A46R-01 Non-Small Cell Lung Cancer 447 A403V Missense CRUK0001-R1 Non-Small Cell Lung Cancer (Johns 447 A403V Missense CRUK0001-R3 K676E Missense CRUK0001-R3 K676E Missense CRUK0027-R2 Small Cell Lung Cancer (Johns 80 X632_splice Splice scl_ucologne_2015_S02093 K353Rfs*12 FS del scl_ucologne_2015_S02277 Scl_ucologne_2015_S02277			V491L	Missense	TCGA-22-1016-01
Pan-Lung Cancer (TCGA, Nat 1144 X233_splice Splice TCGA-43-6770-01 Genet 2016) TGB TCGA-33-4587-01 TGGA-55-8205-01 Genet 2016) T798P Missense TCGA-55-8205-01 V670L Missense TCGA-62-734-01 G95 Missense TCGA-62-7731-01 A99S Missense TCGA-62-7734-01 X195_splice Splice TCGA-12-A524-01 R357S Missense TCGA-13-A524-01 R357S Missense CRUK0001-R1 Non-Small Cell Lung Cancer 447 A403V Missense CRUK0001-R2 (TRACERx, NEJM & Nature 2017) 447 A403V Missense CRUK0001-R3 K676E Missense CRUK0001-R3 K676E Missense S58208 Small Cell Lung Cancer (Johns 80 X632_splice Splice S58208 Small Cell Lung Cancer (Johns 80 X632_splice Splice scl_ucologne_2015_S02093 Hopkins, Nat Genet 2012) K353Rfs*12 FS del scl_ucologne_2015_S02277			G147V	Missense	TCGA-39-5035-01
Pan-Lung Cancer (TCGA, Nat 1144 Y633Lfs*2 FS ins TCGA-33-4587-01 Genet 2016) T798P Missense TCGA-55-8205-01 V670L Missense TCGA-55-8506-01 G395 Missense TCGA-62-731-01 A99S Missense TCGA-62-746R-01 W477R Missense TCGA-12-A524-01 R357S Missense TCGA-13-A524-01 R357S Missense CRUK0001-R1 Non-Small Cell Lung Cancer 447 A403V Missense CRUK0001-R2 (TRACERx, NEJM & Nature 2017) 447 A403V Missense CRUK0001-R3 K676E Missense CRUK0001-R3 K676E Missense S5208 Small Cell Lung Cancer (Johns 80 X632_splice Splice scl_ucologne_2015_S02093 Hopkins, Nat Genet 2012) K053Rfs*12 FS del scl_ucologne_2015_S02277			X233_splice	Splice	TCGA-43-6770-01
Genet 2016) T798P Missense TCGA-55-8205-01 V670L Missense TCGA-55-8506-01 G395 Missense TCGA-65-731-01 A99S Missense TCGA-62-A46R-01 W477R Missense TCGA-27341-01 X195_splice Splice TCGA-24-01 R357S Missense LUAD-LIP77-Tumor A403V Missense CRUK0001-R1 Non-Small Cell Lung Cancer 447 A403V Missense CRUK0001-R2 (TRACERx, NEJM & Nature 2017) 4403V Missense CRUK0001-R3 K676E Missense CRUK0001-R3 K676E Sb5208 Small Cell Lung Cancer (Johns 80 X632_splice Splice scl_ucologne_2015_S02093 Hopkins, Nat Genet 2012) K353Rfs*12 FS del scl_ucologne_2015_S02277	Pan-Lung Cancer (TCGA, Nat	1144	Y633Lfs*2	FS ins	TCGA-33-4587-01
V670LMissenseTCGA-55-8506-01G395MissenseTCGA-56-7731-01A99SMissenseTCGA-62-A46R-01W477RMissenseTCGA-27341-01W477RMissenseTCGA-12-A524-01R357SMissenseLUAD-LIP77-TumorA403VMissenseCRUK0001-R1Non-Small Cell Lung Cancer447A403VMissense(TRACERx, NEJM & Nature 2017)A403VMissenseCRUK0001-R2K676EMissenseCRUK0001-R3K676ES85208Small Cell Lung Cancer (Johns80K353Rfs*12FS delsclc_ucologne_2015_S02277	Genet 2016)		T798P	Missense	TCGA-55-8205-01
G395 Missense TCGA-56-7731-01 A99S Missense TCGA-62-A46R-01 W477R Missense TCGA-62-A46R-01 W477R Missense TCGA-22-7341-01 X195_splice Splice TCGA-12-A524-01 R357S Missense LUAD-LIP77-Tumor A403V Missense CRUK0001-R1 (TRACERx, NEJM & Nature 2017) A403V Missense CRUK0001-R2 (TRACERx, NEJM & Nature 2017) A403V Missense CRUK0001-R3 K676E Missense CRUK0001-R3 K676E Missense CRUK0001-R3 K676E Missense CRUK0001-R3 K676E Missense S8208 Small Cell Lung Cancer (Johns 80 K353Rfs*12 FS del sclc_ucologne_2015_S02277			V670L	Missense	TCGA-55-8506-01
A99SMissenseTCGA-62-A46R-01W477RMissenseTCGA-92-7341-01X195_spliceSpliceTCGA-12-A524-01R357SMissenseLUAD-LIP77-TumorA403VMissenseCRUK0001-R1Non-Small Cell Lung Cancer447A403VMissense(TRACERx, NEJM & Nature 2017)A403VMissenseCRUK0001-R2K676EMissenseCRUK0001-R3K676EMissenseCRUK0027-R2E398KMissenseS85208Small Cell Lung Cancer (Johns80K632_spliceSplicescl_ucologne_2015_S02093K938Rfs*12FS delscl_ucologne_2015_S02277			G395	Missense	TCGA-56-7731-01
W477RMissenseTCGA-92-7341-01X195_spliceSpliceTCGA-13-A524-01R357SMissenseLUAD-LIP77-TumorR403VMissenseCRUK0001-R1Non-Small Cell Lung Cancer447A403VMissenseCRUK0001-R2(TRACERx, NEJM & Nature 2017)A403VMissenseCRUK0001-R3K676EMissenseCRUK0027-R2E398KMissenseCRUK0027-R2Small Cell Lung Cancer (Johns80X632_spliceSplicesclc_ucologne_2015_S02093Hopkins, Nat Genet 2012)K353Rfs*12FS delsclc_ucologne_2015_S02277			A99S	Missense	TCGA-62-A46R-01
X195_spliceSpliceSpliceTLCA-L3-A524-01R357SMissenseLUAD-LIP77-TumorA403VMissenseCRUK0001-R1Non-Small Cell Lung Cancer447A403VMissenseCRUK0001-R2(TRACERx, NEJM & Nature 2017)A403VMissenseCRUK0001-R3K676EMissenseCRUK0027-R2E398KMissenseS8208Small Cell Lung Cancer (Johns80X632_spliceSplicesclc_ucologne_2015_S02093Hopkins, Nat Genet 2012)K353Rfs*12FS delsclc_ucologne_2015_S02277			W477R	Missense	TCGA-92-7341-01
Non-Small Cell Lung Cancer 447 A403V Missense CRUK0001-R1 Non-Small Cell Lung Cancer 447 A403V Missense CRUK0001-R2 (TRACERx, NEJM & Nature 2017) A403V Missense CRUK0001-R3 K676E Missense CRUK0027-R2 E398K Missense 585208 Small Cell Lung Cancer (Johns 80 X632_splice Splice sclc_ucologne_2015_S02093 Hopkins, Nat Genet 2012) K353Rfs*12 FS del sclc_ucologne_2015_S02277			X195_splice	Splice	ILGA-L3-A524-01
Non-Small Cell Lung Cancer 447 A403V Missense CRUK0001-R1 (TRACERx, NEJIM & Nature 2017) 447 A403V Missense CRUK0001-R2 K676E Missense CRUK0027-R2 E398K Missense CRUK0027-R2 Small Cell Lung Cancer (Johns 80 X632_splice Splice sclc_ucologne_2015_S02093 Hopkins, Nat Genet 2012) K353Rfs*12 FS del sclc_ucologne_2015_S02277			K35/5	Missense	LUAD-LIP//-IUMOF
Kon-Sman Cen Lung Cancer Cancer (Johns) 447 A403V Missense CRUK0001-R2 (TRACERx, NEJM & Nature 2017) A403V Missense CRUK0001-R3 K676E Missense CRUK0027-R2 E398K Missense 585208 Small Cell Lung Cancer (Johns) 80 X632_splice Splice sclc_ucologne_2015_S02093 Hopkins, Nat Genet 2012) K353Rfs*12 FS del sclc_ucologne_2015_S02277	Non Small Coll Lung Cancer	447	A403V	Missense	
K405V Missense CRUK001-RS K676E Missense CRUK0027-R2 E398K Missense 585208 Small Cell Lung Cancer (Johns 80 X632_splice Splice sclc_ucologne_2015_S02093 Hopkins, Nat Genet 2012) K353Rfs*12 FS del sclc_ucologne_2015_S02277	TRACERY NEIM & Nature 2017)	447	A403V	Missense	
Korob Missense CKKK027-K2 E398K Kissense 585208 Small Cell Lung Cancer (Johns 80 X632_splice Splice sclc_ucologne_2015_S02093 Hopkins, Nat Genet 2012) K353Rfs*12 FS del sclc_ucologne_2015_S02277	(INACLAA, MEJINI & MALUIC 2017)		K676F	Missense	CRUK0027-R2
Small Cell Lung Cancer (Johns 80 X632_splice Splice scl_ucologne_2015_S02093 Hopkins, Nat Genet 2012) K353Rfs*12 FS del sclc_ucologne_2015_S02277			F398K	Missense	585208
Hopkins, Nat Genet 2012) K353Rfs*12 FS del sclc_ucologne_2015_S02277	Small Cell Lung Cancer (Johns	80	X632 splice	Splice	sclc ucologne 2015 S02093
	Hopkins, Nat Genet 2012)		K353Rfs*12	FS del	sclc_ucologne_2015_S02277

In this case, we found that the highest level of copy number alteration is occurred due to the shallow deletion type of genetic alteration. The second most significant genetic change is done by amplification type of copy number alteration. Overall, variant natures of genetic alteration in ACE2 are assembled to contribute to lung cancer development (Fig. 4c).

Next, we went through a similar type of analysis for interpreting the genetic alterations in the CXCL10 mRNA regarding lung cancer. In this

instance, we pointed out 6 missense type of mutations with a somatic mutation frequency of 0.1% where 2 duplicate mutations were present (Table 2). The mutations are evidenced at 4 different locations of the 98 amino acids long CXCL10 protein sequence (Fig. 4d). We then analyze genetic alteration frequency in the CXCL10 mRNA distinct numbers of lung cancer studies. In this regard, we observed the highest rate of alteration frequency (2.79%) in CXCL10 mRNA for LUSC. Interestingly, am-



Fig. 4. The Functional characterization of ACE2 and CXCL10 in lung cancer development by using the cBioPortal (a) 64 Mutations in ACE2 protein sequence was figured out by using lollipop plots; (b) Three types of alteration frequencies of ACE2 in lung cancer were presented in bar diagram; (c) The expression level of differently categorized genetic alterations was presented for ACE2; (d) Total 6 mutation in CXCL10 protein was presented by lollipop plots. (e) Three variant types of alteration frequency in CXCL10 were presented in the bar diagrams. (f) The expression level regarding the multiple categories of genetic alteration was represented in graphical plots based on the log scale (RNA seqV2).

plification is the only type of alteration in this case. However, for other cases, fluctuation in alteration frequency and changes in the nature of alteration was observed. For instance, the TCGA data of LUSC represented alteration frequency only for amplification type whereas UCOLOGENE 2015 revealed that alterations in CXCL10 of small cell lung cancer are completely mediated by mutation type genetic change (Fig. 4e). Last of all, we did an extensive analysis of the different expression levels of unique alteration types in CXCL10 mRNA. From this analysis, we experienced that amplification is the most upregulated copy number alteration considering their level of expression while shallow deletion is the most common type of alteration considering their expression frequency (Fig. 4f). Overall, the functional characterization of ACE2 and CXCL10 by using multiple lung cancer studies provides some of the vital evidence of their intimate relationship with lung cancer development.

3.4. Determination of ACE2 and CXCL10 assisted PPI network associated with COVID-19 development

Multiple numbers of genes are responsible directly or indirectly for COVID-19 development. Using the Comparative Toxicogenomics Database (CTD), we managed to identify 12,347 genes associated with COVID-19 disease based on their inference score. Each of these genes has either curated association to the disease or an inferred association *via* a curated chemical interaction. Extracting the huge data set, 15 curated genes were identified as the biomarkers or therapeutic targets for COVID-19 treatment in which ACE2 and CXCL10 were included (Table 3). By utilizing the translated protein sequences of these 15 genes a PPI network was constructed through the STRING database (Fig. 5). Following this, we found out 74 connecting edges among the selected

Table 2

A list of genetic alternations in ACE2 protein sequences associated with lung cancer development.

Cancer study	Sample size	Protein change	Mutation type	Sample ID
Pan-Lung Cancer (TCGA, Nat	1144	S34I	Missense	TCGA-L9-A7SV-01
Genet 2016)		K69N	Missense	TCGA-NJ-A4YP-01
Lung Adenocarcinoma (TCGA,	566	S34I	Missense	TCGA-L9-A7SV-01
PanCancer Atlas)		K69N	Missense	TCGA-NJ-A4YP-01
Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018)	75	C10F	Missense	nsclc_mskcc_2018s29
Small Cell Lung Cancer (U Cologne, Nature 2015)	120	L24V	Missense	sclc_ucologne_2015_S02322

Table 3

The List of curated genes directly associated with COVID-19 development.

Name of gene	Curated association	Inference score
CCL2	Biomarker	30.22
TNF	Biomarker	28.55
IL6	Biomarker	25.40
IL10	Biomarker	25.01
IL1B	Biomarker	21.27
IL8	Biomarker	20.75
AGT	Biomarker	18.01
IL2	Biomarker	15.73
CCL3	Biomarker	11.73
CXCL10	Biomarker	11.46
ACE2	Biomarker and Therapeutic Target	9.16
TMPRSS2	Biomarker	6.38
IL2	Biomarker	6.19
IL2RA	Biomarker	3.20
CSF3	Biomarker	2.28



Fig. 5. A protein-protein interaction network representing the interconnection of the functional proteins associated with COVID-19 infection. ACE2 is mainly interconnected with AGT, TMPRSS2, and IL1B whereas CXCL10 is interlinked with other cytokines such as IL-6, IL-7, TNF, and IL-10. Many other cross-linked interconnections are also found for other proteins.

Abbreviation: CXCL10 – C-X-C motif 10; ACE2- Angiotensin converting enzyme 2; AGT- Angiotensin; CXCL8- C-X-C motif 8; IL6- Interleukin 6; TMPRSS2- Transmembrane protease, serine 2; IL2- Interleukin 2; IL2RA- Interleukin 2 receptor alpha chain; CCL2- C-C motif ligand 2; TNF- Tumor necrosis factor; IL10- Interleukin 10; CSF3- Colony stimulating factor; IL1B- Interleukin 1 beta; CCL3- C-C motif ligand 3; IL7- Interleukin 7

proteins, though the predicted edges were only 16 according to the information provided by the database itself. That means the network represents more interconnections than the expected outcome. Such affluence indicates that the proteins are functionally connected, as a group. We also found that ACE2 and CXCL10 proteins are interconnected along with other protein components associated with COVID-19 development. It is clear evidence that ACE2 and CXCL10 are crucial proteins contributing to the COVID-19 disease progression.

3.5. Estimation of the commonly co-expressed genes of ACE2 and CXCL10 associated with lung cancer and COVID-19 development

To identify the genes that are correlated with the expression of ACE2 and CXCL10, we went through a comprehensive analysis by using the R2: Genomics and Visualization web portal. From here, we explored the co-expressed genes of ACE2 and CXCL10 responsible for lung cancer and COVID-19 development by utilizing the TCGA data. We identified a total of 6793 co-expressed genes of the ACE2 associated with LUAD and LUSC whereas the number of co-expressed genes related to COVID-19 was 10803. Similarly, we determined 5999 genes that are coaltered with CXCL10 in the case of lung cancer development and 6430 co-expressed genes associated with COVID-19. A restriction of p-value < 0.01 was applied to each case of the analysis. After that, the lists representing co-expressed genes of ACE2 and CXCL10 in each of the cases of lung cancer and COVID-19 were utilized to construct Venn diagrams using the Bioinformatics and Evolutionary Genomics web tool. The two Venn diagrams revealed the commonly co-expressed genes of ACE2 and CXCL10 associated with lung cancer and COVID-19 development. In the case of ACE2, 3544 co-expressed genes were identified commonly associated with both of the disease conditions (Fig. 6a). On the other hand, 2088 genes were identified which are co-altered along with the expression of CXCL10 in both cases of lung cancer and COVID-19 (Fig. 6b).

3.6. Molecular assessment of the functional approaches of ACE2 and CXCL10

To interpret the functional activity of ACE2 and CXCL10 in lung cancer and COVID-19, we used the lists of previously identified co-expressed genes using the PANTHER database. First of all, we processed a query for determining the molecular activity of ACE2 by listing the previously identified 3544 commonly co-expressed genes. We analyzed multiple types of molecular activity and found that a major portion (37.1%) of the genes (803) are involved in the binding activity (Fig. 7a). Through extended analysis, we observed the variant nature of the binding activities of corresponding 803 genes. Following this analysis, we observed that most of the genes are involved in protein binding activity (53.5%; 430 genes) (Fig. 7b).

After that, we looked forward to investigating the functional attitude of CXCL10 using the list of previously determined 2048 commonly co-expressed genes associated with lung cancer and COVID-19 development. By analyzing the biological processes, we observed that the listed genes are involved in performing a wide range of biological activities such as cellular process, biological regulation, metabolic process, immune system process, localization, biogenesis, etc. (Fig. 7c). However, by remarking our research aims, we performed an extended analysis with the co-expressed genes of CXCL10 involved in different immune processes. Regarding this analysis, we explored that 46 genes are involved in immune response, 5 genes act for immune system development, 12 genes are responsible for leukocyte activation whereas 10 genes are responsible for leukocyte migration, 12 genes contribute to the activation of immune response and 20 genes lead the immune effecT.B. Mahmood, A.S. Chowdhury, M.U. Hossain et al.



Current Research in Microbial Sciences 2 (2021) 100022

Fig. 6. Graphical representation of commonly co-expressed genes of ACE2 and CXCL10 in lung cancer and COVID-19 (a) The Venn diagram represents 3544 co-expressed genes of ACE2 (b) The Venn diagram represents 2088 commonly co-expressed genes of CXCL10 associated with both of the diseases.

tor process (Fig. 7d). Overall, many of the co-expressed genes of CXCL10 are found to play an important role in various branches of the immune system along with the functional activity of CXCL10.

4. Discussion

Because COVID-19's clinical manifestations varied from cohort to cohort, it is quite important to address the key stakeholders for this variation for developing proper therapeutics against the disease as well as prevention and management in different cohorts (Landman et al., 2020, Vaninov, 2020). Previous studies have consistently held both ACE2 receptors as well as cytokine storms for the severe prognosis of COVID-19 and preexisting conditions like lung cancer just make the situation worse for the patients (Sidaway, 2020, Wan et al., 2020). Evidence that CXCL10 is one of the significant cytokines which is directly involved in the event of cytokine storm, tissue damage of the lung cell and subsequent development of Acute Respiratory Disease Syndrome (ARDS) indicates its importance as a biomarker for COVID-19 (Goh et al., 2020, Xu et al., 2020, Liu et al., 2020, Mehta et al., 2020). Based on these evidence, we analyzed the mRNA expression of ACE2 and CXCL10 in LUAD and LUSC attributing multidisciplinary parameters. We found that in almost all cases an over-expression of ACE2 in LUAD and LUSC was seen as compared to the cases with the normal conditions (Fig. 3a-d). Previous studies have reported the age groups exceeding 60 years as the most vulnerable to COVID-19 and our expression analysis of ACE2 and CXCL10 aligns with their finding. We observed that the most upregulated ACE2 expression was found for the age group 61-80 years which is reported as the topmost vulnerable age group for the COVID-19 infection (Liu et al., 2020). CXCL10 expression was found at an elevated level in both LUAD and LUSC (3e-h) which also indicates CXCL10's involvement in lung carcinoma and the event of cytokine storm and subsequent disease fatality. We then applied a comparative analysis of ACE2 and CXCL10 expression in LUAD and LUSC based on their expression score by normal and tumor cells. In this case, we observed a higher expression score of these two genes in both LUAD and LUSC compared to the normal conditions (Fig. 3i). The results of these initial analyses provided primary evidence that overexpression of ACE2 receptor and enhanced CXCL10 cytokine expression might be the major possible reason for increased susceptibility and fatality of lung cancer patients towards COVID-19. Because overexpression of the ACE2 gene may result in increased binding activity of the ACE2 protein and therefore higher susceptibility towards the COVID-19 infection. On the other hand, the elevated expression of CXCL10 may also be involved in alveolar collapse by proceeding to the excessive secretion of cytokines (Fig. 8).

In regards to the aforementioned fact, we performed a functional assessment of ACE2 and CXCL10. From the Comparative Toxicogenomics Database (CTD), we retrieved the most significant 15 proteins which have a direct association with the COVID-19 disease development where ACE2 and CXCL10 proteins are also included (Table 3). Upon establishing a protein-protein interaction network (PPIN) among these pro-

teins we found 74 nodes of interaction among the 15 proteins in which ACE2 and CXCL10 were predominantly explored as the hub proteins because the major portion of the nodes was assisted by these two proteins (Fig. 5). Previous studies on cancer have extensively used PPI network analysis methods to analyze causes based on a core protein in relation to other proteins by interpreting nodes and functionalities (Rezaei-Tavirani et al., 2017, Losuwannarak et al., 2020, Nibbe et al., 2010, Chuang et al., 2017, 2007). PPI networks have been a lucrative approach in the past years merely because they can answer queries relevant to the association of a particular protein with diseases at a molecular level. Moreover, PPI networks are equally helpful in contrasting expression levels of particular genes and proteins between normal cells and infected cells (Tang et al., 2011, Ideker et al., 2002, Hao et al., 2016, Dittrich et al., 2008). Our systematic analysis aligning to the general approach of PPIN analysis targeted two intricately important proteins ACE2 and CXCL10 involved in the cascade of biological processes triggered by the presence of a SARS-CoV-2 infection. Upon subjecting these two molecules, we observed that in both normal individuals and individuals with lung cancer, these two proteins are extensively involved in the overall pathophysiology and prognosis. This outcome provides extended evidence about the functional involvement and significant contribution of ACE2 and CXCL10 to the SARS-CoV-2 mediated infection development. Besides confirming the significance of ACE2 and CXCL10 in COVID-19 development, we also realized the need of determining their role in lung cancer development to establish a connection between lung cancer and COVID-19 through these targeted genes. Therefore, we performed a functional characterization of ACE2 and CXCL10 in lung cancer by analyzing the mutations and copy number alterations in their protein sequence based on 21 lung cancer studies. In total, 64 mutations at 24 different locations of the ACE2 protein were found where the maximum frequency of alteration was 3.49%. On the other hand, 6 mutations at 4 different locations of the protein sequence were found for CXCL10 where the highest level of alteration frequency was 2.79% (Fig. 4). Mutations, amplifications, deletions, copy number alterations, and all other genetic changes are referred to as the functional significance of any gene in cancer development. Therefore, these results provided supportive evidence of the active participation of ACE2 and CXCL10 in lung cancer development.

For identifying and analyzing co-expressed genes of ACE2 and CXCL10 associated with lung cancer and COVID-19 we constructed two Venn diagrams by listing the co-expressed genes of ACE2 and CXCL10 in each case of lung cancer and COVID-19. A total of 3544 commonly co-expressed genes associated with both lung cancer and COVID-19 were identified for ACE2 whereas the number of the commonly co-expressed genes of CXCL10 was 2088. These commonly co-expressed genes were utilized to interpret the functional nature of ACE2 and CXCL10 both in lung cancer and COVID-19 development. By analyzing the molecular activity of the 3544 commonly co-expressed genes for ACE2, we found that 803 genes are involved in the binding activity (Fig. 7a and b). The active participation of these commonly co-expressed genes in binding



Fig. 7. Evaluation of the functional attitudes of ACE2 and CXCL10 represented by using the PANTHER database (a) Eight classes of the molecular activity of ACE2 and its co-expressed genes were presented through a pie chart (b) In total 17 variant types of binding activities of 803 genes were represented by using a bar chart (c) Total 20 unique types of biological activities of CXCL10 and its co-expressed genes were represented using a pie chart (d) Six differently categorized immune system processes of the corresponding 68 co-expressed genes were presented through a bar chart.



Fig. 8. A comparative illustration representing the possible reasons for the higher susceptibility and fatality rate of the COVID-19 infected lung cancer patients rather than the COVID-19 infected healthy patients.

activity can be beneficial to ACE2 for showing a more efficient binding affinity towards SARS CoV-2 viral spike protein. This functional enforcement of the receptor activity of ACE2 may increase the susceptibility of lung cancer patients towards COVID-19. On the other hand, to interpret the functional attitude of CXCL10 we used the list of 2088 commonly co-expressed genes of CXCL10 associated with lung cancer and COVID-19. By analyzing the biological activity of 2088 co-expressed genes, we found that 68 genes are directly involved in the immune system (Fig. 7c and d). At the early stage of our study, we showed overexpression of CXCL10 in lung cancer and by doing the functional analysis of CXCL10 we confirmed its association with immune response. By combining these two analyses, we can predict that overexpressed CXCL10 along with the presence of other cytokines causes cytokine storms in the alveoli of the COVID-19 infected lung cancer patients (Fig. 8). This cytokine storm results in the alveolar collapse due to lung cell damage by excessive neutrophil recruitment to the site of infection. In the prolonged severe condition, the damaged alveoli cause decreased gas exchange and result in difficulty in breathing. Finally, the ultimate destruction of the alveoli results in the obstruction of breathing and causes the patient's death

(Szklarczyk et al., 2017, Mi et al., 2013). Overall, enforcing the viral entry and cytokine storm, the over-expressed ACE2 and CXCL10 become major factors of the higher susceptibility and fatality rate of lung cancer patients towards COVID-19 infection.

5. Conclusion

As biological processes are overly complex, analyzing a single signaling molecule or receptor in regards to a broad spectrum pathophysiological phenomenon triggered by different pathogens or diseases can raise concerns. However, the key findings of this research revealed some of the strong evidences confirming the direct interconnection of ACE2 and CXCL10 with lung cancer development. Therefore, based on this systemic analysis, we can pinpoint that ACE2 and CXCL10 are possible biomarkers whose higher expressions are responsible for the greater susceptibility and fatality of lung cancer patients towards the COVID-19 infection. This finding can facilitate in choosing drug targets for the management of COVID-19 through therapeutics and evaluating the type of measures that are required to be adapted for individuals with lung cancer. Although the in silico facts about the association of ACE2 and CXCL10 overexpression in lung cancer patients and COVID-19's severe manifestations in these individuals coincide with peripheral relevant studies, further wet-lab experiments are required for in-depth understanding.

Declaration of Competing Interest

The authors declare no competing interest.

CRediT authorship contribution statement

Tousif Bin Mahmood: Conceptualization, Methodology, Formal analysis, Writing – original draft. Afrin Sultana Chowdhury: Supervision, Writing – original draft, Writing – review & editing. Mohammad Uzzal Hossain: Validation, Writing – review & editing. Mehedee Hasan: Formal analysis, Writing – original draft. Shagufta Mizan: Writing – original draft, Writing – review & editing. Md. Mezbah-Ul-Islam Aakil: Formal analysis, Writing – original draft. Mohammad Imran Hossan: Writing – review & editing.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

- Abassi, Z., Knaney, Y., Karram, T., Heyman, S.N., 2020. The lung macrophage in SARS– CoV-2 infection: a friend or a foe ? Front. Immunol. 11, 1–5.
- Antonio, C., Inmaculada, A.M., Manuel, A., Marianela, B., Natalia, G., Javier, S., Marta, A., Clara, T.V., Luis, Á.E., María, d.M.-M., Tatiana, M., Mar, G., Rosa, Á., Miguel, M., 2020. Outcomes of COVID-19 in patients with lung cancer treated in a tertiary hospital in Madrid. Front. Oncol. 10, 1777.
- Barnes, B.J., et al., 2020. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J. Exp. Med. 217, 1–7.
- Cerami, E., et al., 2012. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404.
- Chandrashekar, D.S., et al., 2017. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19, 649–658.
- Chuang, H.Y., Lee, E., Liu, Y.T., Lee, D., Ideker, T., 2007. Network-based classification of breast cancer metastasis. Mol. Syst. Biol. 3, 140.
- Chuang, H.-Y., Lee, E., Liu, Y.-T., Lee, D., Ideker, T., 2017. Protein-protein interaction network analysis for a biomarker panel related to human esophageal adenocarcinoma. Asian Pac. J. Cancer Prevent. 18 (12), 3357–3363.
- Dai, M., et al., 2020. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 10, 783–792.
- Dittrich, MT, Klau, GW, Rosenwald, A, Dandekar, T, Müller, T., 2008. Identifying functional modules in protein-protein interaction networks: an integrated exact approach. Bioinformatics 24 (13), i223–i231.
- Dong, E., Du, H., Gardner, L., 2020. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 20, 533–534.
- Faria, N.R., Suchard, M.A., Rambaut, A., Streicker, D.G., Lemey, P., 2013. Simultaneously reconstructing viral cross- species transmission history and identifying the underlying constraints. R. Soc. 368, 1–9.
- Feng, Y., Wan, H., Liu, J., Zhang, R., Ma, Q., Han, B., Xiang, Y., Che, J., Cao, H., Fei, X., Qiu, W., 2010. The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol. Rep. 23, 941–948.
- Goh, K.J., et al., 2020. Rapid progression to acute respiratory distress syndrome: review of current understanding of critical illness from COVID-19 infection. Ann. Acad. Med. 49, 108–118.
- Guo, Y., et al., 2020. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak an update on the status. Mil. Med. Res. 7, 1–10.
- Hao, T., Peng, W., Wang, Q., Wang, B., Sun, J., 2016. Reconstruction and application of protein–protein interaction network. Int. J. Mol. Sci. 17, 907.
- Huang MD, P.C., Wang MD, Y., Li MD, P.X., Ren PhD, P.L., Zhao MD, P.J., Hu MD, Y., et al., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506.
- Ideker, T., Ozier, O., Schwikowski, B., Siegel, A.F., 2002. Discovering regulatory and signalling circuits in molecular interaction networks. Bioinformatics 18, S233–S240.
- Indwiani Astuti, Y., 2020. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS– CoV-2): an overview of viral structure and host response. Diabetes Metab. Syndr. Clin. Res. Rev. 14, 407–412.
- Jennifer, M., 2020. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA Netw. Open 323, 17–20.
- Kanda Dr., N., Shimizu, T., Tada, Y., Watanabe, S., 2007. IL-18 enhances IFN-γ-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. Eur. J. Immunol. 27, 338–350.

- Koster, J., Versteeg, R., 2008. R2: genomics analysis and visualization platform. Oncogenomics 11, 2017.
- Landman, A., Feetham, L., Stuckey, D., 2020. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 21, 335–337.
- Larran, P. & Saeys, Y. Gene expression a review of feature selection techniques in bioinformatics. 23, 2507–2517 (2007).
- Lee, EY, Lee, ZH, Song, YW., 2009. CXCL10 and autoimmune diseases. Autoimmun. Rev. 8, 379–383.
- Li, T., et al., 2017. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 77, e108–e110.
- Liu, K., Chen, Y., Lin, R., Han, K., 2020. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J. Infect. 80, e14–e18.
- Liu, Y., et al., 2020. Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury. Natl. Sci. Rev. 7, 1003–1011.
- Losuwannarak, N., Maiuthed, A., Kitkumthorn, N., Leelahavanichkul, A., Roytrakul, S., Chanvorachote, P., 2020. Gigantol targets cancer stem cells and destabilizes tumors via the suppression of the PI3K/AKT and JAK/STAT pathways in ectopic lung cancer xenografts. Cancers 11, 2032.
- Mattingly, C.J., et al., 2006. The comparative toxicogenomics database: a cross-species resource for building chemical-gene interaction networks. Toxicol. Sci. 92, 587–595.
- Mehta, P., et al., 2020. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033–1034.
- Mehta, V., et al., 2020. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 10, 1–7.
- Mi, H., Muruganujan, A., Casagrande, J.T., Thomas, P.D., 2013. Large-scale gene function analysis with the panther classification system. Nat. Protoc. 8, 1551–1566.
- Nibbe, R.K., Koyutürk, M., Chance, M.R., 2010. An integrative -omics approach to identify functional sub-networks in human colorectal cancer. PLOS Comput. Biol. 6 (1), e1000639.
- Qian, Y.-R., Guo, Y., Wan, H.-Y., Fan, L., Feng, Y., Ni, L., Xiang, Y., Li, Q.-Y., 2020. Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition. Oncol. Rep. 29, 2408–2414.
- Rahman, F., Mahmood, T.B., Amin, Al, Alam, R., Jharna, J.F., Samad, A., Ahammad, F., 2020. A multi-omics approach to reveal the key evidence of GDF10 as a novel therapeutic biomarker for breast cancer. Inform. Med. Unlocked 21 ISSN 2352-9148.
- Rezaei-Tavirani, M., Rezaei-Tavirani, S., Mansouri, V., Rostami-Nejad, M., Rezaei-Tavirani, M., 2017. Protein-protein interaction network analysis for a biomarker panel related to human esophageal adenocarcinoma. Asian Pac. J. Cancer Prevent. 18 (12), 3357–3363.
- Routley, N., 2020. Visualizing what Covid-19 does to your body. Vis. Capatalist. https://www.visualcapitalist.com/wp-content/uploads/2020/04/covid-19-affects-the-body.html.
- Saini, K.S, Heras, B.de I., Castro, J.de, Venkitaraman, R., Poelman, M., Srinivasan, G., Saini, M.L., Verma, S., Leone, M., Aftimos, P., "Giuseppe, 2020. Effect of the COVID-19 pandemic on cancer treatment and research. Lancet Haematol. 7.
- Shereen, M.A., Khan, S., Kazmi, A., Bashir, N., Siddique, R., 2020. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J. Adv. Res. 24, 91–98.
- Sidaway, Peter, 2020. COVID-19 and cancer: what we know so far. Nat. Rev. Clin. Oncol. 17.
- Spinelli, A., 2020. COVID-19 pandemic: perspectives on an unfolding crisis. BJS Soc. 107, 785–787.
- Szklarczyk, D., et al., 2017. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 45, D362–D368.
- Tang, X., Wang, J., Liu, B., et al., 2011. A comparison of the functional modules identified from time course and static PPI network data. BMC Bioinform. 12, 339.
- Tang, Z., Kang, B., Li, C., Chen, T., Zhang, Z., 2019. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47, W556–W560.
- Vaninov, N., 2020. In the eye of the COVID-19 cytokine storm. Nat. Rev. Immunol. 20, 277.
- Wan, Y., Shang, J., Graham, R., Baric, R.S., Receptor, F.L., 2020. Recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of. J. Virol. 94, 1–9.
- Xu, H., et al., 2020. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. J. Oral Sci. 12, 1–5.
- Xu, Z., et al., 2020. Case Report Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. 8, 420–422.
- Yang, J., et al., 2020. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int. J. Infect. Dis. 94, 91–95.
- Yang, Y., Shen, C., Li, J., Yuan, J., Yang, M., Wang, F., Li, G., Li, Y., Xing, L., Peng, L., Wei, J., Cao, M., Zheng, H., Wu, W., Zou, R., Li, D., Xu, Z., Wang, H., Zhang, M., Zhang, Z., Liu, L., L., Y., 2020. Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome. MedRxiv Prepr. 2019, 1–26.
- Zhang, H., Penninger, J.M., Li, Y., Zhong, N., Slutsky, A.S., 2020a. Angiotensin converting enzyme 2 (ACE2) as a SARS CoV 2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 46, 586–590.
- Zhang, H., Quek, K., Chen, R., Chen, J., Chen, B., 2020b. Expression of the SARS-CoV-2 receptor ACE2 reveals the susceptibility of COVID-19 in non-small cell lung cancer. J. Cancer 11, 5289–5292.
- Zhou, F., et al., 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062.